Kidney care leadership enters a new Medicare chapter as CKCC gives way to LEAD
Keith A. Bellovich, D.O., MBA, arrives in this discussion with a long clinical record and an equally deep policy footprint in kidney care. He currently serves as chief nephrologist at Strive Health, after more than three decades in private practice with St. Clair Nephrology and seven years in hospital administration as chief medical officer with Henry Ford St. John Hospital. His background bridges bedside nephrology, executive leadership, and national advocacy, a combination that matters when payment policy begins to reshape how chronic kidney disease is managed across Medicare populations.
Bellovich earned his medical degree from Michigan State University College of Osteopathic Medicine, completed residency and nephrology fellowship at Henry Ford Hospital in Detroit, and later obtained an MBA from the University of Michigan Ross School of Business. The training path is unusually relevant here. Kidney disease sits at the intersection of long-term clinical management, care coordination, hospitalization risk, and resource allocation, so a leader who understands both the medical and operational sides of care brings a different lens to policy debates than a purely academic or administrative voice would.
He has also held prominent national leadership posts. Bellovich is the immediate past president of the Renal Physicians Association and has served on its board since 2012. More recently, he was elected chair-elect of Kidney Care Partners, the nation’s largest non-partisan kidney care coalition, and serves as its representative to the National Quality Forum. He has also played a driving role in the Kidney Care Quality Alliance’s work on dialysis performance metrics, pressing for CMS measures that are more valid and more meaningful for dialysis facilities nationwide.
Policy transitions in Medicare do not happen in a vacuum.
When one care model ends and another begins, clinicians who manage kidney disease often face the practical question of whether continuity, quality measurement, and patient-centered coordination will survive the handoff. The headline tied to Bellovich’s byline asks exactly that: what happens to kidney care when Medicare’s CKCC model sunsets and LEAD begins? Even without the body text of the article, the question signals a familiar tension in nephrology policy. Patients with kidney disease frequently need repeated monitoring, medication adjustment, dialysis planning, vascular access decisions, transplant consideration, and close attention to comorbidity burden. Any payment or accountable care framework that does not recognize those demands risks measuring the wrong things or rewarding the wrong behaviors.
Bellovich’s career suggests why he is positioned to argue this point. Dialysis care is not just about throughput or facility-level metrics. It is about whether quality measures reflect outcomes that matter to patients and clinicians, whether facilities are judged on data that capture real performance, and whether care models support rather than fragment longitudinal management. The Kidney Care Quality Alliance’s efforts to develop dialysis performance metrics point directly to this challenge. In chronic kidney disease, a narrowly framed measure can miss the difference between services that are technically delivered and care that is clinically coherent. A metric can look clean on paper and still fail to capture symptom burden, hospitalization risk, or the complexity of treating patients whose kidney disease is layered over diabetes, hypertension, cardiovascular disease, and frailty.
The stakes are especially high because kidney care often unfolds across settings. A patient may move from outpatient nephrology to inpatient care, from conservative management to dialysis preparation, and sometimes to transplant evaluation. Each transition creates opportunities for error, delay, or loss of information. Payment models that reward coordination can improve the odds that these transitions are managed deliberately. Models that fragment responsibility can do the opposite. In that sense, the policy debate around CKCC and LEAD is not merely technical. It is a structural question about how Medicare wants kidney care delivered, tracked, and improved.
Bellovich’s leadership at Kidney Care Partners also carries weight because the coalition is non-partisan and broad-based by design. That kind of platform is often where consensus around quality, access, and sustainability gets translated into recommendations that regulators can actually use. The National Quality Forum role adds another layer of influence, since measure validity is one of the central fault lines in dialysis quality policy. If a measure is poorly constructed, it can distort practice rather than improve it. If it is well designed, it can make care more transparent and more actionable for clinicians, patients, and payers alike.
Why the Medicare transition matters for nephrology practice
The transition from CKCC to LEAD, as posed in the article title, implies more than a change in acronym. It marks a broader question about whether Medicare’s evolving ACO framework will account for the realities of chronic kidney disease care. Nephrology is expensive, longitudinal, and highly sensitive to coordination failures. It also sits at a crossroads with primary care, cardiology, endocrinology, and hospital medicine, which means any model that isolates kidney disease from the rest of the care continuum is likely to underperform.
Bellovich’s profile makes clear why nephrology advocates continue to press CMS for measures that are meaningful rather than merely convenient. Facilities and clinicians need tools that reflect outcomes tied to patient experience, safety, and clinical decision-making. Dialysis metrics that fail to capture the complexity of kidney disease can push organizations toward documentation games instead of care improvement. Metrics that align with real clinical priorities can support earlier intervention, better planning, and fewer preventable disruptions.
His dual identity as clinician and administrator also reflects a broader truth in kidney care policy: the people who shape the system most effectively are often those who understand both the medical course of disease and the organizational mechanics of delivery. Bellovich’s bio places him squarely in that group. The question now is whether the Medicare framework that follows CKCC will give nephrology the same level of attention, specificity, and care coordination that patients with advanced kidney disease require.